Refractive surgery: Edited by Roy ChuckPostrefractive surgery dry eyeQuinto, Guilherme G; Camacho, Walter; Behrens, Ashley Author Information The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence to Ashley Behrens, MD, The Wilmer Eye Institute, 600 North Wolfe St., 255 Woods Building, Baltimore, MD 21287-0005, USA Tel: +1 410 502 0461; e-mail: [email protected] Current Opinion in Ophthalmology: July 2008 - Volume 19 - Issue 4 - p 335-341 doi: 10.1097/ICU.0b013e3283009ef8 Buy Metrics Abstract Purpose of review To report the recently published literature on ocular surface changes after refractive surgery, as well as the outcomes of treatment modalities on postrefractive surgery dry eye. Recent findings Cyclosporine, the first US Food and Drug Administration approved agent to treat the underlying pathological mechanism of chronic dry eye, has demonstrated promising results in dry eye patients. Further, there may be an additive effect of topical cyclosporine and punctal occlusion. Femtosecond lasers for corneal flaps in laser in-situ keratomileusis seem to induce fewer signs and symptoms of dry eye and may be attributed to the creation of thinner flaps. Summary Dry eye is one of the most common complications after photorefractive keratectomy and laser in-situ keratomileusis. Keratorefractive surgery is known to cause damage to the corneal sensory nerves. Several studies have demonstrated a decrease in corneal sensation, tear secretion, and tear film stability several months after keratorefractive surgery. For patients with preoperative dry eye, the ocular surface must be treated accordingly prior to surgery. © 2008 Lippincott Williams & Wilkins, Inc.